Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 4/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816677 | 0.90 | HTR2C (0.51) | IKBKBHTR2CCHUKTOP2ALCK | |
| SCHEMBL2818464 | 0.88 | HTR2C (0.47) | IKBKBHTR2CCHUKTOP2ALCK | |
| SCHEMBL2816389 | 0.88 | HTR2C (0.47) | IKBKBHTR2CCHUKTOP2ALCK | |
| SCHEMBL2815052 | 0.88 | HTR2C (0.47) | IKBKBHTR2CCHUKTOP2ALCK | |
| SCHEMBL2815174 | 0.87 | IKBKB (0.48) | IKBKBHTR2CCHUKTOP2ALCK | |
| SCHEMBL2817059 | 0.85 | MAPT (0.47) | IKBKBHTR2CCHUKTOP2ASMN1; SMN2 | |
| SCHEMBL2816951 | 0.84 | HTR2C (0.44) | IKBKBHTR2CCHUKTOP2ALCK | |
| SCHEMBL2818524 | 0.84 | HTR2C (0.44) | IKBKBHTR2CCHUKTOP2ASMN1; SMN2 | |
| SCHEMBL2813932 | 0.83 | MAPT (0.51) | IKBKBHTR2CCHUKTOP2ASMN1; SMN2 | |
| SCHEMBL2815092 | 0.83 | IKBKB (0.46) | IKBKBHTR2CCHUKTOP2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | claimed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | claimed |
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | IKBKB 855/4885HTR2C 1292/4885CHUK 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.